Answers are grounded in this paper and cite their sources.
THE QUESTION OF WHETHER systemic hormonal therapies can effect genital tract HIV-1 RNA shedding is plausible since selected cytokine production in the genital tract, which can be influenced by the hormonal milieu, may modulate the replication of HIV-1.1 The observation that genital tract HIV-1 RNA shedding fluctuates during the menstrual cycle also suggests a hormonal influence on HIV expression.2 In addition, Ghosh3 has shown up-regulation of HIV transcription can occur after steroid hormones bind to hormone-responsive elements within the HIV-1 long terminal repeat. Although prior studies performed in African women found hormonal contraception to be associated with proviral HIV-1 DNA cervical shedding4,5 (reflecting HIV-1 infected cells), no study has noted an association between hormonal contraception use and genital tract HIV-1 RNA shedding,4–6 and it is not clear how the HIV-1 DNA results relate to infectiousness in vivo. Only 1 cross-sectional study looking at the influence of hormonal contraception on genital tract HIV-1 RNA shedding has been previously performed in American women.7 We conducted an additional study in American women to evaluate a possible association by employing both a cross-sectional and longitudinal design. HIV-infected women were recruited from the HIV Outpatient Clinic in New Orleans, Louisiana, from June 2002 to January 2004. Women were invited to participate in a study to examine multiple issues of sexually transmitted infections if they were at least 18 years of age and were scheduled to undergo a primary care gynecological examination. The study was approved by both the Tulane and Louisiana State University Health Science Center Institutional Review Boards, and informed consent was obtained from all study participants. The primary objective of the parent study was to evaluate the association of Trichomonas vaginalis (TV) on genital tract HIV-1 RNA shedding.8 The parent study included 2 arms—a cross-sectional arm and a prospective arm. All women diagnosed with trichomoniasis (TV+) and a subset of women who had negative cultures for Trichomonas vaginalis (TV−) at baseline were invited to participate. The subset of TV− women were chosen by their antiretroviral therapy (ARV) status (on vs. off), which was matched to the ARV status of the TV+ cases. Participants received $25.00 (baseline) or $50.00 (follow-up) reimbursement for their time and effort. All participants were interviewed at baseline and the subset in the prospective arm were interviewed again at 1- and 3-month follow-up visits with a computer-assisted structured interview (CASI) to assess sociodemographic, clinical, and behavioral characteristics. Clinical data were obtained through gynecological examinations (performed by the patient’s medical provider using a standard protocol) and blood and urine specimens (submitted for Chlamydia and Gonorrhea testing). Specimen collection for obtaining study specimens has previously been described.9 For detection and quantitation of genital HIV-1 RNA, secretions were collected from the vaginal vault on Dacron swabs. Secretions were eluted from the swab in 1 mL of phosphate-buffered saline, and were separated into cellular and supernatant fractions. Virions in the supernatant fraction were collected by high-speed centrifugation (16,000g) for 1 hour at 4°C. Virion RNA was purified using Trizol reagent (Invitrogen), and 50% of the isolated RNA from each sample was used for HIV-1 quantification with the Roche Amplicor HIV-1 Monitor Assay. Viral quantity was reported as copies per vaginal sample, with a minimum level of detection at 50 copies per sample. Shedding was defined as a categorical variable with expression of >50 copies of HIV per sample designated as detectable and ≤50 copies per sample designated as undetectable. Plasma HIV-1 RNA levels were determined similarly, using 1 mL of peripheral blood plasma. HIV-1 RNA copies/mL of plasma were determined using the Roche Amplicor HIV-1 Monitor Assay’s ultrasensitive protocol and reported as copies per milliliter. Hormonal contraception use was ascertained by both CASI and provider-completed case report forms and did not differ by method with the exception that occasionally study participants neglected to include all methods used on the CASI. Women included in this analysis were nonpregnant women with a uterus, who were less than 43 years old and sexually active, and who had specimens available for HIV-1 RNA detection (N = 126). The association between hormonal contraception use and genital tract HIV-1 RNA shedding was compared among women at both baseline and over time using Likelihood Ratio χ2 and logistic regression methods (with generalized estimating equations performed for longitudinal analyses). One hundred eight of the 126 women included at baseline had repeated observations over time. Bonferroni corrections were employed, where applicable, for multiple testing. Table 1 shows demographic and clinical characteristics of the study population. Table 2 outlines the use of ARV and hormonal contraception. As expected, the proportion of women on any ARVs differed greatly between women with detectable versus undetectable genital tract HIV-1 RNA. The use of ARV therapy was significantly associated with genital tract HIV-1 RNA detection, with women on any ARV being less likely to have detectable virus compared with women not on ARV (crude OR: 0.25, 95% CI: 0.11–0.54). ARV use was similar between hormonal contraception users and nonusers (55.6% vs. 49.0%) There was no significant interaction between hormonal contraception use and genital tract RNA HIV-1 shedding according to ARV status (P = 0.3458).TABLE 1: Selected Characteristics of Study Participants Stratified by Hormonal Contraceptive UseTABLE 2: Selected Characteristics of Study Participants (N = 126)As shown in Table 2, 26.7% of women with detectable genital tract HIV-1 RNA compared with 24.7% of women without detectable HIV-1 RNA were on some form of hormonal contraception (crude OR: 1.11, 95% CI: 0.48–2.55). The most popular method was depot medroxyprogesterone. There was no difference in genital tract HIV-1 RNA shedding between women on medroxyprogesterone only versus those on combination hormonal methods (crude OR: 0.467, 95% CI: 0.101–2.1561). After adjusting for all variables in Table 1, the baseline relationship between genital tract HIV-1 RNA shedding and hormonal contraceptive use was 0.600 (95% CI: 0.157–2.291) in multivariate analysis. This relationship was unchanged if the variable for plasma HIV-1 RNA was removed. The relationship between hormonal contraception use and genital tract HIV-1 RNA detection was also examined separately over time for women with repeated measurements. In this subgroup, we identified no difference in the prevalence of genital tract HIV-1 RNA between women on and not on hormonal contraception (crude OR: 1.31, 95% CI: 0.43–3.96), as further demonstrated in Figure 1. The longitudinal relationship between genital tract HIV-1 RNA shedding and hormonal contraceptive use was 0.59 (95% CI: 0.13–2.72) and this relationship also did not change with removal of the plasma HIV-1 RNA variable.Fig. 1: Proportion of women with detectable HIV-1 vaginal RNA over time according to hormonal contraceptive status.Higher plasma HIV-1 RNA was associated with higher vaginal HIV-1 RNA levels among the women in this sample (Pearson correlation coefficient = 0.25131, P = 0.0087). Two women with nondetectable (<50 copies/mL) plasma HIV-1 RNA had detectable HIV-1 genital RNA (21,006 and 18,448 copies/mL). Both women were taking ARVs. To make sure that additional factors were not confounding the association between hormonal contraception and HIV-1 RNA genital tract shedding, differences in hormonal contraception use according to plasma HIV-1 RNA levels, sexually transmitted infection status, CD4 cell count, and age were examined and are shown in Table 1. Even after adjusting for these factors, no difference in detectable genital tract HIV-1 RNA according to hormonal contraception use was noted. The adjusted effect measure for hormonal contraception use and genital tract shedding in the screening arm at baseline was 0.56 (95% CI: 0.21–1.58) after adjusting for high plasma HIV-1 RNA level, CD4 cell count, and age. After adjusting for all factors in Table 1, the baseline relationship between genital tract shedding and hormonal contraceptive use was 0.60 (95% CI: 0.16–2.29). If the model did not include plasma HIV RNA, the effect measure was 0.69 (95% CI: 0.19–2.52). The longitudinal relationship between genital tract shedding and hormonal contraceptive use was 0.59 (95% CI: 0.13–2.72), and if plasma HIV RNA was not included in the model, the effect measure increased to 0.66 (95% CI: 0.15–2.84). Although several studies have looked at the influence of hormonal contraception on genital tract HIV-1 RNA shedding,4–7 only 1 prior study has been performed in American women,7 a cross-sectional study which enrolled women within the Women’s Interagency HIV Study (WIHS). Our study is the first performed in American women to evaluate the association between hormonal contraception and genital tract HIV-1 RNA shedding using a longitudinal design in addition to the cross-sectional analysis. The WIHS cohort had less advanced HIV disease as measured by proportion with CD4 <200 cells/μL (18% vs. 39%) but actually were more likely to be on any ARVs (61% vs. 51%) compared with our study subjects.7 These factors should have decreased the chance of detecting genital tract HIV-1 RNA, but, interestingly, a higher proportion of WIHS participants had shedding compared to our study cohort (64% vs. 36%). However, the effect measure for ARV treatment on genital tract shedding was similar between the WIHS study and our study (OR of 0.3–0.4 vs. 0.25). The phenomenon of genital tract HIV-1 RNA shedding among women with nondetectable HIV-1 RNA plasma levels on ARV treatment was noted in both studies [16 of 86 (16%) in WIHS cohort7 and 2 of 64 (3%) in this study]. Several other studies have found both a significant association between plasma and genital tract HIV-1 RNA levels6,7,10–13 and a protective effect from ARVs.7,10,11 Our study adds additional reassuring information pertaining to ARV therapy and it lends further support for the lack of an association between hormonal contraception use and genital tract HIV-1 RNA shedding. Similar to the findings from other investigators,7,10 selected participants in this study with undetectable plasma HIV-1 RNA still had detectable genital HIV-1 RNA. This study did have many limitations. The study population was selected from the larger parent study and may not be representative of the general adult female population with HIV. A substantial proportion of women on ARV therapy had detectable plasma and genital HIV-1 RNA suggesting probable compliance issues. The small size of the study population reduced the statistical power to determine differences in the different strata being analyzed. Regardless, this pilot study does provide interesting observations and additional larger studies evaluating potential compartment influences on genital tract HIV-1 RNA shedding are warranted.
No takes yet. Share an insight, caveat, or question.
Clark et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: